Professional
Added to YB: 2025-05-08
Pitch date: 2025-04-21
GRFS [neutral]
Grifols, S.A.
+18.43%
current return
Author Info
White Falcon Capital is a value-investing fund that aspires to buy and hold a collection of wonderful publicly listed businesses run by aligned and like-minded managers and owners. Follow on Twitter/X.
Company Info
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Market Cap
EUR 5.4B
Pitch Price
EUR 8.02
Price Target
N/A
Dividend
3.45%
EV/EBITDA
9.52
P/E
14.27
EV/Sales
2.25
Sector
Biotechnology
Category
turnaround
White Falcon Capital Portfolio Holding: Grifols, S.A. - $GRFS
GRFS (holding update): Leading player in oligopolistic plasma-derived therapies market. Family-owned Spanish multinational recovering from mismanagement, poor governance, COVID challenges & high debt. New management implementing operational improvement plan now showing inflection in business performance.
Read full article (1 min)